How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

923 results for

Anxiety Non-pharmacologic Management

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Covid-19: Management of palliative care in hospital during the coronavirus pandemic

and support for ward staff, for example, syringe drivers, prescribing, conversations to plan treatment escalation. • Help to facilitate rapid discharge out of hospital using established connections with hospices, community palliative care teams and primary and community health care services. Symptom management Even though many patients will survive and recover from coronavirus, managing their symptoms during this period remains important. This guidance assumes that a patient has received all appropriate (...) referral to a coroner is required by virtue of its notifiable status Coordination of support for the bereaved family and those close to the patient should be managed by the hospital’s bereavement services, signposting them to locally and nationally available support services, including those provided by the voluntary sector. National guidance on the use of PPE, verification of death and medical certification should be followed. 5 | Clinical guide for the management of palliative care in secondary care

2020 Covid-19 Ad hoc guidelines

22. Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause

Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause Management Briefs eBrief-no117 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no117 -- Health Services Research & Development Management eBrief no. 117 » Issue 117 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Report: Non-Pharmacologic Treatments (...) hormone therapy and, in part, to uncertain efficacy and safety of pharmacologic treatments, many women with VMS seek non-hormonal, non-pharmacologic treatment options (i.e., herbal remedies, yoga, tai chi). Therefore, investigators with VA's Evidence-based Synthesis Program (ESP) located in Durham, NC, have summarized and updated the evidence from systematic reviews on selected non-pharmacologic approaches for the management of menopause-associated VMS and health-related quality of life. Investigators

2016 Veterans Affairs - R&D

23. British guideline on the management of asthma

Doughty Street London WC1N 2PL www.brit-thoracic.org.uk SIGN and BTS consent to the photocopying of this guideline for the purpose of implementation in the NHS in England, Wales, Northern Ireland and Scotland.Contents 1 Introduction 1 1.1 The need for a guideline 1 1.2 Remit of the guideline 1 1.3 Statement of intent 4 2 Key recommendations 6 2.1 Diagnosis 6 2.2 Monitoring 7 2.3 Supported self management 7 2.4 Non-pharmacological management 7 2.5 Pharmacological management 7 2.6 Inhaler devices 8 2.7 (...) Predicting future risk of asthma attacks 32 4.4 Physiological measures 36 4.5 Other approaches 37 5 Supported self management 38 5.1 Effectiveness of supported self management 38 5.2 Components of a self-management programme 38 5.3 Self management in specific patient groups 42 5.4 Adherence and concordance 45 5.5 Implementation in practice 48 6 Non-pharmacological management 50 6.1 Primary prevention 50 6.2 Secondary prevention 557 Pharmacological management 62 7.1 Intermittent reliever therapy 63 7.2

2019 SIGN

24. Risk reduction and management of delirium

• pain control • prevention, early identification and treatment of postoperative complications • maintaining optimal hydration and nutrition • regulation of bladder and bowel function • provision of supplementary oxygen, if appropriate. R All patients at risk of delirium should have a medication review conducted by an experienced healthcare professional. 2.3 Non-pharmacological treatment R Healthcare professionals should follow established pathways of good care to manage patients with delirium (...) and/or distress, using non- pharmacological means only if possible (see section 7 for pharmacological treatment). • Communicate the diagnosis to patients and carers, encourage involvement of carers and provide ongoing engagement and support. • Aim to prevent complications of delirium such as immobility, falls, pressure sores, dehydration, malnourishment, isolation. • Monitor for recovery and consider specialist referral if not recovering. • Consider follow up (see section 8).6 Risk reduction and management

2019 SIGN

25. Guidelines for diagnosing and managing pediatric concussion

and manage significant, prolonged complaints based on specific symptoms, etiology and the time since injury. B 5.9 Assess and treat any physical, cognitive and neurological deficits. B 5.4a(i) Place every child/adolescent on a program of sleep hygiene. C 5.4a(ii) Screen for factors that may influence the child/adolescent’s sleep/wake cycle. B 5.4a(iii) Consider non-pharmacological treatments to improve sleep. C 5.4a(iv) Consider prescribing medication on a short-term basis if sleep has not improved. C (...) medications (especially stimulants); • Mood or anxiety disorders; • Early morning headaches (possible sleep apnea); • Unhealthy habits (lack of exercise, variable sleep-wake schedule, excessive napping, excessive time spent in bed, exercising close to bedtime). Why: To identify factors that could be treated or changed to improve the child/adolescent’s sleep and recovery. Level of evidence: B. 5.4a(iii): Consider non-pharmacological treatments to improve sleep. When: On re-evaluation. Who: Health care

2019 CPG Infobase

26. Guidelines on Supraventricular Tachycardia (for the management of patients with) Full Text available with Trip Pro

by agreement of the expert panel after thorough deliberation. The document was peer-reviewed by official external reviewers. The strengths of the recommendations and levels of evidence of particular management options were weighed and graded according to predefined scales, as outlined above in Tables and , respectively. Overall, these Guidelines include evidence and expert opinions from several countries. The pharmacological and non-pharmacological antiarrhythmic approaches discussed may therefore include (...) Guidelines on Supraventricular Tachycardia (for the management of patients with) 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC) | European Heart Journal | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie

2019 European Society of Cardiology

27. European Academy of Neurology guideline on the management of medication-overuse headache

the prevalence of MOH. Onlyonerandomizedstudyhasevaluatedthee?cacy of non-pharmacological preventive strategies in MOH [39]. A German multi-center study compared the impact of written information alone with a brochure versus written information plus behavioral minimal- contact training in preventing MOH 1–2 years later in subjects with migraine (n = 182). The minimal-contact training had an additional focus on psychoeducation andpain-copingstrategies.Thesubjectshadanaverage of 11 headache days per month (...) that shows clear evidence of their e?cacy, especially in patients with MOH. However, given the prevalence of depressive symptoms in patients with MOH, they could be useful in this group of patients. From a theoretical point of view, the e?ect of pre- ventive treatment of MOH with topiramate, onabo- tulinum toxin A or monoclonal antibodies targeting CGRP may be potentiated by the adoption of non- pharmacological treatments [64]. There are, however, no randomized trials investigating the combination of non

2020 European Academy of Neurology

28. Diagnosis and management of epilepsy in adults

Diagnosis and management of epilepsy in adults SIGN 143 • Diagnosis and management of epilepsy in adults A national clinical guideline Evidence May 2015 · Revised 2018KEY TO EVIDENCE STATEMENTS AND GRADES OF RECOMMENDATIONS LEVELS OF EVIDENCE 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 - Meta-analyses, systematic reviews, or RCTs with a high risk of bias (...) ; or Extrapolated evidence from studies rated as 2 + GOOD PRACTICE POINTS ? Recommended best practice based on the clinical experience of the guideline development group NHS Evidence has accredited the process used by Scottish Intercollegiate Guidelines Network to produce guidelines. Accreditation is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2008 edition (www.sign.ac.uk/guidelines/fulltext/50/index.html). More information on accreditation can

2018 SIGN

29. 'Worried to death': the assessment and management of anxiety in patients with advanced life-limiting disease, a national survey of palliative medicine physicians. Full Text available with Trip Pro

%). Only 8% used psychiatric criteria. Most physicians reported difficulties managing anxiety (93%). Only 33% thought they had adequate training in this area. Most had difficulty accessing psychological and/or psychiatric services (71%, 64% respectively). The majority used a combination of pharmacological and non-pharmacological treatments for anxiety. The most frequently prescribed first-line medications for patients with a prognosis of days to weeks were benzodiazepines (93%), usually lorazepam (...) . Findings demonstrate the infrequent use of screening tools, variation in prescribing practice, potentially inappropriate use of benzodiazepines for patients with a prognosis of months, training gaps and poor access to psychological and psychiatric services in the UK. This highlights the need for formal training, further research into the pharmacological management of anxiety in this population and evidence-based national guidance to support clinical decision-making and service development.

2017 BMC Palliative Care

30. A Standardized Meditation Technique "Body-scan", in the Management of Anxiety in Hospitalized Parkinsonian Patients

in out-patients and by using standardized 8 weeks programs. The team has experienced in the hospitalization unit that methods derived from the MBSR program such as the "body scan", administered by the paramedical personnel, is of great help for the non-pharmacological management of anxiety and agitation in PD, avoiding physical contention in many cases. Based on this experience the study aims at evaluating the feasibility and preliminary efficacy of a simple and standardized administration (...) A Standardized Meditation Technique "Body-scan", in the Management of Anxiety in Hospitalized Parkinsonian Patients A Standardized Meditation Technique "Body-scan", in the Management of Anxiety in Hospitalized Parkinsonian Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2017 Clinical Trials

31. Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B

: Retrospectively 10 years ] Based on Registry data Duration of anti-anxiety medications as measured by expected doses of medicines. [ Time Frame: Retrospectively 10 years ] Based on Registry data Pharmacological and non-pharmacological treatments for management of Health-Related Quality of Life (HRQoL) impairment, including treatment of pain [ Time Frame: Inclusion in survey study ] Assessed by Health Care Professional (HCP) survey in Part B1 Pharmacological and non-pharmacological treatments for management (...) of HRQoL impairment, including treatment of anxiety [ Time Frame: Inclusion in survey study ] Assessed by HCP survey in Part B1 Pharmacological and non-pharmacological treatments for management of HRQoL impairment, including treatment of depression [ Time Frame: Inclusion in survey study ] Assessed by HCP survey in Part B1 The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of pain at each

2017 Clinical Trials

32. Management of Cardiovascular Diseases during Pregnancy Full Text available with Trip Pro

Prevention of hypertension and pre-eclampsia 3207 10.4 Management of hypertension in pregnancy 3208 10.4.1 Background 3208 10.4.2 Non-pharmacological management 3208 10.4.3 Pharmacological management 3208 10.5 Delivery 3208 10.6 Prognosis after pregnancy 3209 10.6.1 Blood pressure post-partum 3209 10.6.2 Hypertension and lactation 3209 10.6.3 Risk of recurrence of hypertensive disorders in a subsequent pregnancy 3209 10.6.4 Long-term cardiovascular consequences of gestational hypertension 3209 10.6.5 (...) Management of Cardiovascular Diseases during Pregnancy We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy | European Heart Journal | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close

2018 European Society of Cardiology

33. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS)

reproductive, metabolic and psychological features. Education, self-empowerment, multidisciplinary care and lifestyle intervention for prevention or management of excess weight are important. Depressive and anxiety symptoms should be screened, assessed and managed with the need for awareness of other impacts on emotional wellbeing. Combined oral contraceptive pills are first- line pharmacological management for menstrual irregularity and hyperandrogenism, with no specific recommended preparations (...) International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS) International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018Publication approval The guideline recommendations on pages 16 to 34 of this document were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 July 2018 under section 14A of the National Health and Medical Research Council Act 1992

2018 European Society of Human Reproduction and Embryology

34. Management of Alcohol-Related Liver Disease

pharmacological treatments for AUD show modest results, and they cannot replace the non-pharmacological management of the addictive process, which is recognised by health author- ities as the most relevant element of treatment. 70,71 In fact, this simply implies to add brief intervention techniques to the usual clinical management of patients with ALD. The effect of brief interventions Thereisalargebodyofevidenceontheef?cacy 72 andeffective- ness 73 of brief interventions to reduce alcohol consumption (...) Management of Alcohol-Related Liver Disease EASL Clinical Practice Guidelines: Management of alcohol-related liver disease q European Association for the Study of the Liver ? Summary The harmfuluseofalcoholhasbeenestimated tocause approx- imately 3.3million deaths every year, corresponding to nearly 6% of all deaths globally. Therefore, the effective management and treatment of alcoholic liver disease is a pertinent public health issue. In the following Clinical Practice Guidelines

2018 European Association for the Study of the Liver

35. Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention

Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03739983 Recruitment Status : Not yet recruiting First Posted : November 14

2018 Clinical Trials

36. Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children

Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03425669 Recruitment Status

2018 Clinical Trials

37. Surveillance, Diagnosis and Management of Clostridium Difficile Infection in Ireland

testing recommendations • Management of patients/residents with suspected/confirmed CDI: New sections on management of patients/residents with potentially infectious diarrhoea, management of Glutamase dehydrogenase(GDH)/Nucleic acid amplification test (NAAT) positive: toxin negative patients/residents • Treatment of CDI: Update on patient/resident management, new section on patients/ residents with IBD, surgical management of CDI and new drugs/non-pharmacological options • Management of outbreaks (...) implementation of this guideline in all Irish healthcare settings as part of an integrated infection prevention and control and patient safety strategy will ensure that patients/residents with CDI are detected in a timely fashion, managed optimally and that cross infection to other patients/ residents is minimised. 13 A National Clinical Guideline Clostridium difficile Infection in Ireland Specifically this guideline: 1. Updates the 2008 guidance for the surveillance, diagnosis, prevention and control

2019 National Clinical Guidelines (Ireland)

38. Assessment and Management of Patients at Risk for Suicide

Making 17 H. Co-occurring Conditions 18 I. Implementation 18 IV. Guideline Work Group 19 V. Algorithm 20 Algorithm A: Identification of Risk for Suicide 21 Algorithm B: Evaluation by Provider 22 Algorithm C: Management of Patients at Acute Risk for Suicide 25 VII. Recommendations 27 A. Screening and Evaluation 29 a. Screening 29 b. Evaluation 31 B. Risk Management and Treatment 35 a. Non-pharmacologic Treatments 35 b. Pharmacologic Treatments 41 c. Post-acute Care 44 d. Technology-based Modalities 47 (...) VA/DoD Clinical Practice Guideline for the Assessment and Management of Patients at Risk for Suicide May 2019 Page 4 of 142 C. Other Management Modalities 50 a. Population & Community-based Interventions 50 D. Knowledge Gaps and Recommended Research 54 a. Screening for Suicide Risk 54 b. Evaluation, Determining Level of Risk, and Relationship to Treatment 54 c. Risk and Protective Factors 54 d. Non-pharmacologic Interventions 55 e. Pharmacologic Interventions 55 f. Post-acute Care Approaches 56 g

2019 VA/DoD Clinical Practice Guidelines

39. Management of Stroke Rehabilitation

Therapy 57 d. Visual Therapy 59 VA/DoD Clinical Practice Guideline for the Management of Stroke Rehabilitation July 2019 Page 4 of 170 E. Mental Health Therapy 61 a. Prevention of Post-Stroke Depression 61 b. Treatment of Post-Stroke Depression 63 c. Treatment of Post-Stroke Anxiety 66 d. Adjunctive Treatment 69 F. Other Functions 72 VII. Research Priorities 74 Appendix A: Identifying Patient Rehabilitation Goals 77 Appendix B: Additional Information on Management of Stroke 80 A. Education 80 B (...) /DoD Clinical Practice Guideline for the Management of Stroke Rehabilitation July 2019 Page 6 of 170 Disability from stroke can present in a myriad of ways depending on the affected area(s) of the central nervous system. The most common presentations include focal weakness and sensory disturbances, speech and swallowing impairments, vision loss or neglect, cognitive problems with inattention or memory loss, as well as emotional difficulties with mood or anxiety. The early management of stroke

2019 VA/DoD Clinical Practice Guidelines

40. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures

Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures | From the American Academy of Pediatrics | Pediatrics '); document.write(''); } function OAS_AD(pos) { if (OAS_version >= 11 && typeof(OAS_RICH)!='undefined') { OAS_RICH(pos); } else { OAS_NORMAL(pos); } } //--> Search (...) for this keyword Source User menu Sections Sign up for highlighting editor-chosen studies with the greatest impact on clinical care. From the American Academy of Pediatrics Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures Charles J. Coté , Stephen Wilson , AMERICAN ACADEMY OF PEDIATRICS , AMERICAN ACADEMY OF PEDIATRIC DENTISTRY Abstract The safe sedation of children for procedures requires a systematic approach

2019 American Academy of Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>